Recombinant Human BTNL9 Fc Chimera Protein, CF

Recombinant Human BTNL9 Fc Chimera (Catalog # 9659‑BT)inhibits IFN-gamma secretion by human peripheral blood mononuclear cells in thepresence of anti-CD3 antibody. The ED50 for this effect is 3‑15 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTNL9 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ fot this effect is 3-15 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human BTNL9 protein
  

  Human BTNL9 (Ser35-Lys256) Accession # Q6UXG8-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6UXG8
• N-terminal Sequence: Ser35
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-69 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTNL9 Fc Chimera Protein, CF

• BTN3
• BTNL9
• butyrophilin 3
• butyrophilin-like 9
• butyrophilin-like protein 9
• UNQ1900/PRO4346
• VDLS1900

Background

Butyrophilin-like 9 (BTNL9) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL9 is a 535 amino acid (aa) type I transmembrane glycoprotein that contains a 222 aa extracellular domain (ECD), a 21 aa helical transmembrane domain, and a 258 aa cytoplasmic domain. The ECD features both an IgV and IgC domain, which is commonplace in the BTN/BTNL proteins, but the IgC domain is relatively weak (1-4). The ECD of human BTNL9 shares 66% and 67% aa sequence identity with rat and mouse, respectively. Human BTNL9 mRNA has been identified in adipose, lung, thymus, spleen, colon, and cardiac tissues, but its highest levels of expression were found in B cells (2, 5). Although the specific function of BTNL9 has yet to be fully elucidated, recombinant BTNL9-Fc has been shown to bind to many immune cells including T cells, B cell, macrophages, and dendritic cells (6). BTNL9 expression has also been found to be down-regulated in colon cancer tumors (5). R&D in house data indicate that BTNL9 protein inhibits the secretion of IFN-gamma from anti-CD3 activated PBMC.

1. Arnett, H.A. et al. (2014) Nat Rev Immunol. 14:5596.
2. Arnett, H.A. et al. (2009) Cytokine 46:370.
3. Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
4. Rhodes, D. et al. (2016) Annu. Rev. Immunol. 34:151.
5. Lebrero-Fernandez, C. et al. (2016) Immun. Inflammation Dis. 4:191.
6. Yamazaki, T. et al. (2010) J. Immunol. 185:5907.

Bioinformatics

• Uniprot:
  • Q6UXG8()